Background {#Sec1}
==========

Lung cancer is one of the leading causes of cancer related deaths worldwide \[[@CR1]\]. Administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) to patients with activating mutations in the *EGFR* gene, especially exon 19 deletions and exon 21 p.L858R point mutations, has significantly improved treatment and outcome of advanced-stage lung cancer patients \[[@CR2]\].

Five to 50% of patients with lung adenocarcinomas carry activating mutations within the *EGFR* gene with huge differences between geographical distribution and populations \[[@CR3]\]. Activating mutations confer patients susceptible to treatment with EGFR-tyrosine kinase inhibitors (TKIs). Objective tumour shrinkage is reported in approximately 75% of patients \[[@CR3]\]. Nevertheless, acquired resistance to TKIs and secondary progression is being observed after a median time of 8 to 14 months in nearly all patients \[[@CR4]\].

Until the emergence of osimertinib, first-line therapies were mostly administered with reversible (gefitinib, erlotinib) \[[@CR5], [@CR6]\] or irreversible TKIs (afatinib) \[[@CR7]\]. Molecular analyses revealed a limited number of different resistance mechanisms. The most frequent mechanism (50--60%) is the gate-keeper point mutation p.T790M which lowers affinity of first-line TKIs to the ATP binding pocket \[[@CR8], [@CR9]\]. Less frequent resistance mechanisms (5--15%) are the activation of bypass receptor tyrosine kinases, such as *ERBB2* and *MET* amplifications \[[@CR10], [@CR11]\]. Infrequently, mutations within the genes encoding the downstream signalling molecules BRAF, KRAS, PIK3CA and CTNNB1 are observed \[[@CR4]\]. A completely different and poorly understood mechanism abolishing sensitivity towards EGFR TKI involves the histological transformation into small cell or sarcomatoid lung cancer phenotypes \[[@CR12]\]. Also compound resistance by multiple mechanisms in the same or in different tumour locations have been encountered \[[@CR13]\].

As different resistance mechanisms require precise diagnostics and elicit a wide portfolio of different and effective second-line therapies \[[@CR14]\], we here addressed the question whether the frequencies of resistance mechanisms differ between first-line therapies with reversible and irreversible TKIs. So far the prevalence of the *EGFR* p.T790M mutation and other resistance mechanisms after treatment with reversible first-generation EGFR TKI was investigated in different studies with low patient numbers (*n* = 37) as well as larger cohorts (*n* = 155) \[[@CR15]\]. Especially, the mutational spectrum of irreversible second-generation EGFR TKI afatinib was only investigated in studies with low patient numbers (*n* = 4, *n* = 20) \[[@CR16], [@CR17]\]. Moreover, these studies included patients with second-line EGFR-TKI treatment. Therefore we compiled diagnostic and follow-up data of two very large German pathology centres.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Patients included into this study were biopsied prior to primary treatment and were diagnosed with non-resectable non-small cell lung cancer revealing an activating *EGFR* mutation in exon 19 or 21 at two study sites (Institute for Pathology, University Hospital Cologne and Institute for Hematopathology, Hamburg). All patients received therapy with one of the first-generation TKIs gefitinib or erlotinib or the second-generation TKI afatinib for a minimum of 6 months duration and were rebiopsied after clinically evident secondary progression. Rebiopsies were evaluated for histology, presence of p.T790M, amplifications in *MET* or *ERBB2*, and mutations in *KRAS, BRAF, PIK3CA, PTEN* or *CTNNB1*. DNA extraction was done as described in detail previously \[[@CR18]\].

All patients consented into treatment according to GCP regulations and into molecular diagnostics according to institutional practice. Procedures were approved by the local Ethics Committees.

Targeted parallel sequencing {#Sec4}
----------------------------

Multiplex PCR-based target enrichment was performed as described in detail previously \[[@CR18], [@CR19]\] using a customized lung cancer panel covering 14 lung cancer related genes. Isolated DNA was amplified with an Ion AmpliSeq Custom DNA Panel (Thermo Fisher Scientific, Waltham, MA, USA), and the Ion AmpliSeq Library Kit 2.0 (Thermo Fisher Scientific) according to the Ion AmpliSeq Library Preparation User Guide (Thermo Fisher Scientific). The panel comprises a subset of cancer relevant genes including: *AKT1*, *ALK, BRAF*, *CTNNB1*, *DDR2*, *EGFR*, *ERBB2*, *KRAS*, *MAP 2 K1*, *MET*, *NRAS*, *PIK3CA*, *PTEN* and *TP53*.

Depending on DNA concentration, DNA was alternatively amplified with an updated version of the above described panel, namely the GeneRead DNAseq Targeted Panel V2 (Qiagen, Hilden, Germany) and the GeneRead DNAseq Panel PCR Kit V2 (Qiagen) according to the GeneRead DNASeq Gene Panel Handbook (Qiagen) as described previously \[[@CR20]\]. This panel covers three additional cancer related genes: *KEAP1*, *FGFR2* and *FGFR3* .

From both types of PCR products, libraries were constructed using the Gene Read DNA Library I Core Kit and the Gene Read DNA I Amp Kit (Qiagen, Hilden, Germany). After end-repair and adenylation, NEXTflex DNA Barcodes were ligated (Bio Scientific, Austin, TX, USA). Barcoded libraries were amplified and then the final library product was quantified with Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific) on the Qubit 2.0 Fluorometer (Thermo Fisher Scientific), diluted and pooled in equal amounts. Finally, 12 pM of the constructed libraries were sequenced on the MiSeq (Illumina, San Diego, CA, USA) with a MiSeq reagent kit V2 (300-cycles) (Illumina) following the manufacturer's recommendations.

Data were exported as FASTQ files. Alignment and annotation was done using a modified version of a previously described method (Peifer et al., 2012). BAM files were visualized in the Integrative Genomics Viewer (<http://www.broadinstitute.org/igv/>, Cambridge; USA). A 5% cut-off for variant calls was used and results were only interpreted if the coverage was \> 200.

Fluorescence in situ hybridisation analyses {#Sec5}
-------------------------------------------

Fluorescence in situ hybridisation (FISH) for *MET* and *ERBB2* amplifications were performed on formalin-fixed, paraffin-embedded tissue specimens using dual-colour labelled hybridization probes (ZytoLight SPEC MET/CEN7 Dual Color Probe and ZytoLightSPEC ERBB2/CEN 17 Dual Color Probe (ZytoVision)). Sections of 1.5 μm tumour material were cut and hybridized overnight with labelled probes for *MET* and *ERBB2* respectively. Review of fluorescence signals was performed at 630x magnification and scored according to defined guidelines \[[@CR21]\];.

Statistical analysis {#Sec6}
--------------------

The Qui-Square Test was used to calculate the differences in prevalence of T790M by the Chi Square Calculator of [www.socscitastics.com](http://www.socscitastics.com). Statistical differences in duration until resistance acquisition under EGFR TKI therapy were calculated using the student's t-test as given by [www.socscitastics.com](http://www.socscitastics.com).

Results {#Sec7}
=======

Patient collection and molecular analysis {#Sec8}
-----------------------------------------

From January 2014 to January 2017, patients with primary sensitizing *EGFR* mutations were treated first-line with either afatinib, or reversible EGFR TKIs erlotinib/gefitinib respectively (Table [1](#Tab1){ref-type="table"}). Progression free survival (PFS) or partial response for at least 6 months (PFS [\>]{.ul} 6 months) under EGFR TKI therapy was chosen as criteria to include only patients without pre-existing *EGFR* p.T790M mutations. 21% of EGFR-mutated and subsequently Afatinib-treated patients progressed in less than 6 month. Approximately 10% of EGFR-mutated and subsequently treated with either erlotinib or gefitinib progressed in less than 6 months. Those patients were not taken into the analysed cohort within this study as they were supposed to be primary resistant (e.g. because of pre-existent resistance clones.) At the time point of clinical progression, patients were re-biopsied for mutational profiling. Upon this, we analysed in total 123 patients, fulfilling the above criteria (Suppl. Table [1](#MOESM1){ref-type="media"}). 55 of those patients had been treated with afatinib and 68 patients had received gefitinib or erlotinib (Fig. [1](#Fig1){ref-type="fig"}). All patients carried an activating *EGFR* mutation before therapy, including 83 primary *EGFR* Exon 19 deletions, 39 primary *EGFR* p.L858R mutations as well as one other *EGFR* mutation (Exon 19 duplication). The patient, carrying the EGFR Exon 19 duplication was excluded from p.T790M prevalence testing. Noteworthy, the distribution of primary *EGFR* mutation types was balanced between the group of patients treated with a reversible and irreversible EGFR TKI, respectively. The most common initial mutation was the *EGFR* deletion p.E746_A750del, followed by the *EGFR* point mutation p.L858R and less common *EGFR* deletions in Exon 19, codons 752 to 759. Sensitivity of baseline biopsy analysis was set to 1% allelic fraction (1% AF). Nevertheless, we further ensured to excluded any possible patients with pre-existing p.T790M mutations via our study design with PFS \> 6 months, as described above. Table 1Clinicopathological features of patients with NSCLC rebiopsied after EGFR TKI resistance acquisitionNo. of cases123baseline morphologyNSCLC 100%**EGFR TKI** afatinib55 gefitinib35 erlotinib33**median age (range)**68 (40--87)  \< 65 years (%)24  \> 65 years (%)76**sex (%)** male53 female70**primary EGFR mutation** EGFR exon 19 deletion89 EGFR exon 21 p.L858R33 EGFR exon 19 duplication1Fig. 1Flow Chart of patient collection and analysis of re-biopsies. 123 patients under EGFR TKI treatment with a PFS [\>]{.ul} 6 months and acquired resistance were rebiopsied (**a**). A cohort of 55 patients acquired resistance under irreversible (**b**) and 68 under reversible EGFR TKI therapy (**c**). Please note, that one afatinib-treated patient carried a primary EGFR Exon 19 duplication and was therefore excluded from the p.T790M prevalence calculation.

Tumour material of EGFR TKI -resistant patients was examined for histological transformation and genetic mutations. All samples showed the histological subtype of adenocarcinoma, except in one tumour sample a small cell lung cancer phenotype was detected. All samples were analysed for genetic mutations within the described target genes to identify common resistance mechanisms besides *EGFR* p.T790M, such as *EGFR* p.S797S, *EGFR* Exon20 duplications and insertions. Further mutations, which may lead to resistance, were taken into account, i.e. activating *CTNNB-1* or *PIK3CA* mutations. Additionally, bypass mechanisms of resistance, which include *MET* high level amplifications, *ERBB2* amplifications were analysed using FISH. *MET* intermediate or low level amplifications (classification criteria as listed in the methods section) were not considered as a mechanism of resistance since their biological/therapeutical relevance is currently under discussion.

Prevalence of acquired resistance mechanisms to first-line irreversible EGFR TKI afatinib {#Sec9}
-----------------------------------------------------------------------------------------

In 22 of 55 patients, the gatekeeper mutation *EGFR* p.T790M (40%) was the most prominent mechanism of resistance to afatinib (Fig. [2](#Fig2){ref-type="fig"}). Two additional patients showed supplementary to p.T790M, *MET* amplifications as additional resistance mechanism (Fig. [3](#Fig3){ref-type="fig"}). 19 of 43 (44%) patients with a primary *EGFR* Exon 19 deletion acquired an *EGFR* p.T790M mutation as resistance mechanism to afatinib. From 11 patients, carrying a primary *EGFR* p.L858R mutation, three (30%) developed the *EGFR* p.T790M gatekeeper mutation in response to afatinib therapy (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). Fig. 2Spectrum of acquired resistance mechanisms. Frequencies of acquired resistance mechanisms under reversible (**a**) and irreversible (**b**) *EGFR* TKI therapy. The *EGFR* p. T790M gatekeeper mutation ist the major mechanism of resistance in reversible as well as irreversible *EGFR* TKI treated patients. Frequencies of alternative resistance mechanisms besides p.T790M are comparable. Note, section p.T790M covers only patients with T790M as exclusive resistance mechanism. Section of multiple resistance mechanisms includes patients with p.T790M plus *MET* or *HER2* amplification.Fig. 3Frequency of p.T790M acquisition. Frequency of total p.T790M acquisition in patients under reversible (**a**) and irreversible (**b**) EGFR TKI therapy for [\>]{.ul} 6 months, respectively. Chi Square statistics identified a significant difference in the prevalence of p.T790M mutation in reversible vs irreversible EGF TKI treated patients (*p* = 0.019)Fig. 4Spectrum of acquired resistance mechanisms in dependence on primary driver mutation. Frequencies of acquired resistance mechanisms under reversible (**a**) and irreversible (**b**) *EGFR* TKI therapy on the background of primary driver mutation. Note, section p.T790M covers only patients with T790M as exclusive resistance mechanism. Section of multiple resistance mechanisms includes patients with p.T790M plus *MET* or *HER2* amplificationFig. 5Frequency of p.T790M acquisition in dependence on primary driver mutation. Frequency of total p.T790M acquisition in patients under reversible (**a**) and irreversible (**b**) EGFR TKI therapy for [\>]{.ul} 6 months, respectively. Frequency of p.T790M acquisition in EGFR Exon 19 mutated patients differs significantly in reversible and irreversible EGFR TKI treated patients determined by Qui Square test (*p* = 0.005)

Among patients without *EGFR* p.T790M mutation, one patient (1.8%) acquired resistance via a high level *MET* amplification. Two patients (3.6%) were determined to acquire resistance via amplification of *ERBB2*. Four of the patients (11%) showed multiple routes of acquired resistance, in detail *MET* high level plus *ERBB2* amplification and *MET* high level amplification plus *EGFR* p.T790M mutation. None of the cases showed an *EGFR* resistance mutation other than p.T790M in response to afatinib (Fig. [2](#Fig2){ref-type="fig"}). In addition, 22 patients (40%) did not show any known mechanism of resistance (Fig. [2](#Fig2){ref-type="fig"}). 4 patients (9%), carrying multiple resistance mechanisms had *EGFR* Exon 19 deletions prior to therapy, while only one patient (10%) showed multiple resistance mechanisms after p.L858R primary *EGFR* mutation. Fifteen patients (35%) with a primary *EGFR* Exon 19 deletion and five (50%) with a primary *EGFR* p.L858R mutation developed resistance to afatinib without any detectable mechanism (Fig. [4](#Fig4){ref-type="fig"}).

Prevalence of acquired resistance mechanisms to first-line reversible EGFR TKI erlotinib and gefitinib {#Sec10}
------------------------------------------------------------------------------------------------------

In 38 of 68 patients, the gatekeeper mutation *EGFR* p.T790M (56%) was the most prominent mechanism of resistance to first-generation EGFR TKI (erlotinib or gefitinib) (Fig. [2](#Fig2){ref-type="fig"}). Six additional patients showed supplementary to p.T790M *MET* or *ERBB2* amplifications as a further resistance mechanism (Fig. [3](#Fig3){ref-type="fig"}).

Among patients without *EGFR* p.T790M mutation, two patients (3%) acquired resistance via a high level *MET* amplification. Another two patients (3%) were determined to acquire resistance via amplification of *ERBB2*. Fifteen of the patients (22%) showed multiple routes of acquired resistance, in detail *MET* high level plus *ERBB2* amplification and *MET* high level amplification plus *EGFR* p.T790M mutation. None of the cases showed an *EGFR* resistance mutation other than p.T790M in response to reversible first-generation EGFR TKI (Fig. [2](#Fig2){ref-type="fig"}). In addition, 10 patients (15%) did not show any known mechanism of resistance (Fig. [2](#Fig2){ref-type="fig"}).

Prevalence of acquired resistance mechanisms to first-line afatinib in comparison to reversible EGFR TKI therapy {#Sec11}
----------------------------------------------------------------------------------------------------------------

Although the gatekeeper mutation *EGFR* p.T790M is the most prominent mechanism of resistance in both cohorts, the prevalence is significantly lower under afatinib therapy in comparison to first-generation EGFR TKI therapy. (45% vs. 65%, *p* = 0.02, see Fig. [3](#Fig3){ref-type="fig"}, Chi-Square Test). Frequencies of alternative resistance mechanisms are comparable between afatinib and first-generation EGFR TKI treated patients. Notably, the proportion of resistant patients with unknown mechanisms of resistance is higher after afatinib therapy (40% vs 15%, *p* = 0.001) Fig. [2](#Fig2){ref-type="fig"}). Regarding the prevalence of *EGFR* p.T790M in combination with either of the primary activating *EGFR* mutations, *EGFR* Exon 19-mutant tumours acquired an *EGFR* p.T790M mutation as resistance mechanism more frequently than tumours with *EGFR* exon 21 mutations after reversible first-generation EGFR TKI therapy (75 and 54%, respectively, *p* = 0.07). Contrary, patients with primary *EGFR* Exon 19 deletions and activating p.L858R mutations acquired an EGFR p.T790M mutation with a comparable prevalence after afatinib treatment (44 and 45%, *p* = 1, Chi Square Test) (Fig. [4](#Fig4){ref-type="fig"}).

Median duration until progression and resistance acquisition under first-generation reversible EGFR therapy {#Sec12}
-----------------------------------------------------------------------------------------------------------

Median period of first-generation EGFR TKI therapy until progression and resistance acquisition was 17 months regarding the total of 68 patients. Median duration until progression differed slightly in the presence of *EGFR* p.T790M mutation (17 vs 14 months) (Fig. [6](#Fig6){ref-type="fig"} b). There was a difference in duration of response in regard to the primary mutation, nevertheless it was not found to be statistically significant. Patients with primary *EGFR* Exon 19 deletions showed a median of 15 month under therapy whereas *EGFR* p.L858R mutated patients showed a median of 24 months PFS (*p* = 0.2, Student's t-test)(Fig. [6](#Fig6){ref-type="fig"} a). Evaluating the PFS combining both types of driver mutation with the acquisition of p.T790M showed a median of 16 months in p.T790M mutated patients with a primary *EGFR* Exon 19 deletion in contrary to 23 months in patients with primary p.L858R (*p* = 0.3, Student's t-test) (Fig. [6](#Fig6){ref-type="fig"} a-c). Fig. 6Duration until resistance acquisition under reversible EGFR TKI therapy. Duration until resistance acquisition under reversible EGFR TKI therapy in dependence on primary driver mutation (**a**) and p.T790M acquisistion status (**b**) respectively and combined (**c**). n.s. =no statistical significance (determined by student's t-test)

Median duration until progression and resistance acquisition under afatinib therapy {#Sec13}
-----------------------------------------------------------------------------------

Median period of afatinib therapy until progression and resistance acquisition was 12.6 months regarding the total of 55 patients. Median duration until progression did not differ significantly in the presence of *EGFR* p.T790M mutation (12 vs 11 months, *p* = 1, Student's t-test) (Fig. [7](#Fig7){ref-type="fig"} b). Specimen showing alternative mechanisms of resistance also had a PFS of 11.8 months. There was no statistical difference in duration of response in regard to the primary mutation. Patients with primary *EGFR* Exon 19 deletions as well as *EGFR* p.L858R mutated patients showed a median of 13 months PFS (Fig. [7](#Fig7){ref-type="fig"} a). Evaluating the PFS combining both types of driver mutation with the acquisition of p.T790M showed a median of 15 months PFS in p.T790M mutated patients with a primary *EGFR* Exon 19 deletion in contrary to 11 months in patients with primary p.L858R (Fig. [7](#Fig7){ref-type="fig"} a-c). Nevertheless, there was no statistically significant difference between both groups. Fig. 7Duration until resistance acquisition under irreversible EGFR TKI therapy. Duration until resistance acquisition under irreversible EGFR TKI therapy in dependence on primary driver mutation (**a**) and p.T790M acquisistion status (**b**) respectively and combined (**c**). n.s. =no statistical significance (determined by student's t-test)

Comparing median PFS under reversible first-generation and irreversible EGFR TKI shows a significant difference in duration with 21 months versus 13 months (*p* = 0.003) (Fig. [8](#Fig8){ref-type="fig"}). Fig. 8Duration until resistance acquisition under reversible and irreversible EGFR TKI therapy. Median PFS until resistance acquisition under reversible (first generation EGFR TKI erlotinib and gefitinib) an irreversible EGFR TKI (afatinib) therapy. Statistical significance is indicated by *p* = 0.003 (determined by student's t-test)

Discussion {#Sec14}
==========

The present retrospective study confirmed that the major mechanism of resistance to afatinib treatment is the *EGFR* p.T790M gatekeeper mutation. Nevertheless, the resistance mutation was detected with a lower prevalence than for reversible EGFR TKIs (erlotinib and gefitinib), 45% vs 64% *p* = 0.02. This is in contrast to previous reports by Wu et al., who showed a similar prevalence for *EGFR* p.T790M after afatinib or reversible EGFR TKI treatment (both 50--60%, *n* = 14,first-line afatinib). Due to the relatively small patient population of first-line afatinib-treated patients with *n* = 14, Wu et al. could not detect a statistically significant difference in the prevalence of EGFR p.T790M acquisition between reversible and irreversible EGFR TKI (*p* = 0.83) ( \[[@CR16]\]). Two further prospective studies by Campo et al. and Tanaka et al. confirmed the lower prevalence of p.T790M in irreversible EGFR TKI treated patients. Campo et al. detected the EGFR p.T790M in 36% of afatinib treated patients (*n* = 11) \[[@CR22]\]. Tanaka and co-workers deciphered the acquisition of p.T790M in 43% of afatinib treated patients (*n* = 37) \[[@CR17]\]. Nevertheless, both studies present small cohorts of afatinib treated patients, which might be too low to draw significant conclusions from. However, our study presents the same numeric trend of a lower prevalence of p.T790M in irreversible EGFR TKI treated patients, which was determined to be statistically significant. Still, *EGFR* p.T790M mutation is the most prominent mechanism of resistance in afatinib treated patients. These findings imply that afatinib-treated patients should equally benefit from treatment with third-generation *EGFR* TKIs, like osimertinib, and need to be screened for emergence of the p.T790M resistance mutation. These novel emerging inhibitors are specific for the *EGFR* p.T790M mutated isoform of the EGFR receptor \[[@CR23], [@CR24]\]. According to El Kadi and coworkers, the formation of EGFR T790M mutation is initiated by AICDA-mediated deamination of the 5-methylcytosine following therapy with either of the EGFR TKI. Nevertheless they observed differential gene expression of AICDA under different treatment conditions (type and dose of EGFR TKI) \[[@CR25]\]. Therefore, a different frequency of T790M acquisition under reversible and irreversible EGFR TKI is conceivable. Moreover the rate of residual growing cancer cells under/after EGFR TKI therapy that can support AICDA- mediated deamination may differ between various TKI, thereby leading to different frequencies of acquired T790M.

Small cell lung cancer transformation has been reported as an alternative mechanism of resistance to first-generation *EGFR* TKI in 3--14% of *EGFR* TKI-treated patients \[[@CR15], [@CR26]\]. This transformation arises upon TKI blockade of *EGFR* signalling in combination with additional mutations, such as inactivation of *RB1*. Within the present study, we did only detect one transformation into small cell lung cancer as resistance mechanism to afatinib therapy and none in the population of first-generation EGFR TKI treated patients. Previous reports on smaller populations did not find transformation as a resistance mechanism to afatinib therapy \[[@CR16], [@CR17]\]. The detection of only one event in a cohort of 54 patients suggests that SCLC transformation is an even rarer event of resistance acquisition than in reversible *EGFR* TKI treated patients. Nevertheless identification of histological transformation, especially of resistant patients, that do not show any molecular mechanism, remains to be critical for treatment recommendations.

One re-biopsy sample showed an activating *CTNNB1* mutation, which is reported to confer resistance to *EGFR* therapies in non-small cell lung cancer \[[@CR27]\]. No other acquired resistance mutations within the *BRAF*, *KRAS* or *PIK3CA* genes were identified in the present study. This could be either characteristic for afatinib treatment or due to the relatively small sample size. Nevertheless, two prospective studies on afatinib treated patients gathered the same observations \[[@CR17], [@CR22]\]. This is in contrast to first-generation *EGFR* TKI treatment, where *BRAF* and *PIK3CA* mutations account for 1 and 5% of resistance to treatment, respectively \[[@CR28]\]. A review of Westover et al. \[[@CR29]\] calculated KRAS mutation as a mechanism of EGFR TKI resistance to be at a frequency of approximately 1% from the majority of previously published data on resistance acquisition. Nevertheless, the underlying studies included all patients under EGFR TKI therapy without taking early progressors upon pre-existent resistance clones into account. Our study in contrast focused on acquired resistance, explicitly excluding early progressors. Only patients with a response to EGFR TKI therapy of at least 6 month were considered to be truly sensitive to therapy and did not carry any subclones with primary resistance mutations. This could be the reason for not identifying any KRAS mutation within the presented cohort of this study. Further, acquired resistance mechanisms via additional *EGFR* mutations (e.g. exon 20 duplication or p.D761Y and p.L747S) were not found either. This is in contrast to previous studies on first-generation EGFR TKIs, where up to 10% of patients under *EGFR* TKI therapy developed rare secondary mutations within the *EGFR* gene \[[@CR30]\].

Activation of alternative pathways is the second common mechanism of resistance to EGFR TKIs. The emergence of anti-pan-HER treatment options (as afatinib) to block these alternative pathways by inhibiting phosphorylation of other HER family members was thought to solve this problem. Nevertheless, within this study, we examined downstream activation of the AKT pathway via amplification of the genes, encoding for *MET* and *ERBB2* to be equally abundant (2% vs 3%) in specific and pan-HER TKI treated patients. Downstream activation of the AKT pathway via amplification of the gene encoding the transmembrane kinase MET was shown to be the prominent alternative mechanism of resistance to first-generation EGFR TKI with 22% of cases \[[@CR30]\]. Resistance acquisition by amplification of *ERBB2* is less common with a reported occurrence of 12% \[[@CR30]\]*.* We here observed *MET* and *ERBB2* amplifications as exclusive mechanisms of resistance at lower frequencies than previously described. Additionally we found those in combination with other acquired resistance mechanisms like p.T790M or as a combination of *ERBB2* and *MET* amplification in the absence of a second-site mutation. The latter one is proposed to signal parallel to EGFR and thereby reactivates downstream signalling of the pathway \[[@CR27]\].

Since, *EGFR* p.T790M is still the most common mechanism of resistance to afatinib, similar to reversible *EGFR* TKI, a comparison of patients´ prognosis and form of disease upon basis of the mutational profile should be made. Previously, patients were shown to have a better prognosis and more indolent form of disease progression upon the presence of an *EGFR* exon 19 deletion \[[@CR31]--[@CR34]\]. Matsuo and co-workers investigated whether there was an association of the (primary) *EGFR* driver mutation with the occurrence and frequency of *EGFR* p.T790M and the period of response to EGFR TKI. They observed a higher occurrence of *EGFR* p.T790M in patients with primary *EGFR* exon 19 deletions in contrast to *EGFR* p.L858R mutation (26 of 41 patients 63% vs 5 of 13 patients 38%) \[[@CR35]\].

These findings are comparable to the prevalences observed within our cohort of first-generation EGFR TKI treatment, where primary EGFR exon 19 mutated patients developed a p.T790M more frequently than p.L858R mutated patients (74 and 54%). Interestingly, frequencies of p.T790M acquisition under afatinib therapy are comparable between primary *EGFR* exon 19 mutated patients and patients with a primary *EGFR* p.L858R mutation (44 and 45%). Matsuo and co-workers did not separate first-generation and second-generation TKIs and had only three afatinib patients in total, while in our study 55 afatinib patients were analysed. Therefore frequencies of co-occurrence of.primary EGFR mutation and p.T790M acquisition coincide with Matsuos´ observations for first-generation EGFR TKI but differ for afatinib. In our study, a clear numeric difference in the co-occurrence of primary driver mutation and frequency of p.T790M development can be seen in reversible EGFR TKI compared to afatinib-treated patients.

Treatment duration until progress under irreversible EGFR TKI in patients with or without acquired p.T790M revealed a comparable duration of 11 and 12 months. For p.T790M mutated patients, Tanaka et al. found a comparable time to progression of 12 months. In contrast, they observed that the duration of p.T790M negative patients under afatinib therapy was much lower with 4.5 months. This strong discrepancy can be explained by the differential study setting. Tanaka et al. analysed all patients under first-line afatinib therapy, while our study excluded early progressors (\< 6 months until clinical progress). We further observed a prolonged PFS of patients under first-generation EGFR TKI, but this finding cannot be compared to results of of clinical trials (e.g.LUX-Lung 7, Archer1050) as our cohort included patients with a PFS [\>]{.ul} 6 months only. The differential study design to all published data on afatinib so far, is the fact, that patients with early progression (\< 6 months) were excluded from this study. The data do not show the median PFS for the different generation of TKI for all patients treated, but only for the cohort with acquired resistance. The values are not comparable to median PFS from other studies, but rather should be seen as duration under therapy until resistance acquisition.

Molecular follow-up is of primary importance for second-line treatment decisions. As we could show within this study, the gatekeeper mutation p.T790M is the most prominent mechanism of resistance among all available first and second-generation EGFR TKI. This favours the majority of relapsed patients for third-generation EGFR TKI therapy (osimertinib), thereby prolonging overall survival. Nevertheless, the differential response of early and late progressors of first and second-generation EGFR TKI patients to osimertinib should be considered. Early progressors are characterized by the pre-existence of sub-clones carrying *EGFR* p.T790M that expand under EGFR TKI therapy. Those are supposed to better respond to osimertinib than late p.T790M resistant tumours that evolve from initially drug-tolerant cells \[[@CR36], [@CR37]\]. In conclusion, late progressors are the target population that profits more from first-line afatinib therapy followed by third-generation EGFR (osimertinib) therapy. In contrast, early progressors are supposed to profit from first-line osimertinib therapy \[[@CR36], [@CR38], [@CR39]\]. Osimertinib, as probably the most effective way to prevent acquisition of the T790M resistance mutation, has been approved for first-line treatment in four countries including the US and Europe \[[@CR40]\]. To stratify patients in the future, allele frequencies of *EGFR* p.T790M subclones in primary tumour samples should be evaluated via ultra-deep parallel sequencing \[[@CR41]--[@CR43]\]. Determination of a clinically relevant cut-off allele frequency could help to distinguish early and late progressors in advance. In future studies, a correlation of *EGFR* p.T790M allele frequency with therapeutic results of first-line afatinib treated patients should be performed.

Furthermore, the determination of tumor mutation burden with type and prevalence of resistance mutation acquisition could be of high interest in the future. Since TMB and efficacy of EGFR-Tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers have been investigated and found to be negatively associated in lung cancer patient treated with EGFR TKI \[[@CR44]\].

The present study is the first retrospective analysis based on a patient number as high as 123 first-line patients including 55 afatinib patients. Moreover, it considers the acquisition of resistance mutation under therapy by including only patients with at least 6 months response to EGFR TKI therapy. Furthermore, exclusively first-line treated tumours samples were considered for data evaluation. Therefore, this study avoids falsification of results by e.g. pre-existent resistance mutations per se or inclusions of patients with prior therapies.

Conclusions {#Sec15}
===========

The *EGFR* p.T790M mutation is the most prominent mechanism of resistance to reversible and irreversible EGFR TKI therapy. Nevertheless there is a statistically significant difference of p.T790M acquisition between the two types of TKI, which might be of importance for clinical therapy decision.
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